Natural killer (NK) cells inhibit early stages of tumor formation, recurrence, and metastasis. Here, we show that NK cells can also eradicate large solid tumors. Eradication depended on the massive infiltration of proliferating NK cells due to interleukin 15 (IL-15) released and presented by the cancer cells in the tumor microenvironment. Infiltrating NK cells had the striking morphologic feature of being densely loaded with periodic acid-Schiffpositive, diastase-resistant granules, resembling uterine NK cells. Perforin-mediated killing by these densely granulated NK cells was essential for tumor eradication. Expression of the IL-15 receptor a on cancer cells was needed to efficiently induce granulated NK cells, and expression on host stromal cells was essential to prevent tumor relapse after near complete destruction. These results indicate that IL-15 released at the cancer site induces highly activated NK cells that lead to eradication of large solid tumors. Cancer Res; 72(8); 1964-74. Ó2012 AACR.
Introduction
Natural killer (NK) cells were originally discovered as peripheral blood lymphocytes that killed certain cancer cells in vitro (1) (2) (3) (4) . In vivo, NK cells inhibited primary tumor formation, tumor recurrence, and metastasis, but usually only at incipient stages [for review see (5) ]. In patients, intratumoral NK cells may reduce metastatic seeding thereby leading to longer survival (6) . Transformed cells often have decreased MHC class I surface expression or have induced expression of ligands for activating receptors on NK cells (7, 8) , and thus are targets of NK cells and their receptors. However, the lack of studies showing NK cells eliminating established solid tumors has cast doubts on the clinical usefulness of NK cells in the therapy of advanced solid tumors.
NK cells can be activated with high doses of interleukin (IL) 2 to proliferate and kill a broad panel of cancer targets and this is being exploited clinically in selected groups of cancer patients (9) (10) (11) ; however, adoptive transfer of NK cells activated in vitro with IL-2 failed to cause tumor regression in melanoma patients (12) . Interleukin 15 (IL-15), discovered in 1994 (13) , also activates human NK cells to kill cancer cells by a perforindependent mechanism (14, 15) . In mice, IL-15 is required for the development and survival of NK cells, and these IL-15 effects depend on expression of the IL-15 receptor a (IL-15Ra) on cells other than the NK cell (16) . Similar to IL-2-induced NK cells, IL-15-induced cells also can prevent cancer development and metastasis (17) (18) (19) . In addition to activating NK cells, IL-15 also activates T cells and thereby induces certain T cellmediated anticancer responses [for review see (20) ]. Nevertheless, whether IL-15 was expressed as a transgene by the cancer cells (21) (22) (23) (24) or given as treatment (25) (26) (27) (28) , anticancer effects remained limited to the prevention of cancer development and metastasis or reduced tumor growth. Therefore, it certainly has remained unclear whether NK cells, when properly activated by IL-15, could have an effect on solid tumors once grown to clinically relevant sizes. Here, we show that, even in the complete absence of T-cell immunity, NK cells can be induced to eradicate large solid tumors.
Materials and Methods
Canada) with permission of H. Hengartner (University Hospital, Switzerland) provided the MC57G fibrosarcoma cell line. 8215 is an MCA-induced cancer line generated in an IL-15Ra-deficient mouse (125 mg MCA). 9604 is a UV-induced cancer line of a K b-/À D b-/À mouse (ref. 30 ; 3 UV exposures per week for half a year; mice provided by A. Chervonsky, The University of Chicago, IL). Both are primary lines that have never been passaged in a mouse. The spontaneous line AG104A of C3H/HeN origin was described (31) . All cell lines were passaged only a few times (less than 1 month) after thawing of working batch freezings, which were generated shortly after obtaining cell lines, to reduce total number of passages to a minimum. Cell lines were authenticated by morphology and growth rate and were Mycoplasma free.
To transduce the 4 cell lines, we used MFG-IL-15HS-IRES-ECFP, MFG-IL-15Ra, or the empty amphotropic virus. Cultures were flow sorted to enrich for positive cells (see Supplementary Materials and Methods for plasmids and details).
ELISA and flow cytometry
M-IL-15 or M-control cells were plated at 4 Â 10 4 cells/mL in a T25 culture flask. Forty-eight-hour supernatants were assayed with the mouse IL-15 Ready-SET-Go! Kit (eBioscience).
Single-cell suspensions from mouse tissue or trypsinized MC57 cells were first blocked with anti-CD16/anti-CD32 antibody then stained with conjugated antibodies (see Supplementary Materials and Methods for antibodies). Flow cytometry data were collected on a FACSCalibur or LSRII, and sorting was carried out on a FACS Aria (all BD Biosciences) and analyzed with FlowJo software (Treestar Inc.).
Tumor challenges, measurements, and reisolations
Mice were injected s.c. with 2.5 Â 10 6 to 5 Â 10 6 cells in 100 mL of phosphate-buffered saline, unless otherwise indicated. Tumor volume was measured every 2 to 5 days with calipers along 3 orthogonal axes and calculated by abc/2. Statistical significance of tumor eradication was determined by the Fisher exact probability test.
Anti-IL-15 (clone M96, provided by Amgen, Seattle, WA) was injected once at 45 mg before cancer cell inoculation and 95 mg weekly thereafter. To deplete NK cells, mice received 100 mg anti-NK1.1 (clone PK136) every 3 to 4 days; NK cell depletion was confirmed by flow cytometry of peripheral blood samples with anti-NK1.1 and anti-CD122. For bone marrow transfers, 3 Â 10 7 cells were injected into each recipient mouse. Details are found in Supplementary Materials and Methods.
Microscopy
Images were taken on the Leitz Laborlux D microscope with a Leitz 63Â/1.4 objective and Zeiss 20Â/0.25 and 6.3Â/0.16 objectives using the QImaging Retiga 2000R camera and QCapture software. Macroscopic images were taken with the Nikon Coolpix 6000 camera.
Histology and immunohistochemistry
Tissue was frozen in ornithine carbamyl transferase with isopentane in dry ice. Sections (4 mm) were cut, dried, mounted, and fixed in acetone. Before staining, endogenous peroxidase was blocked (Dako dual endogenous enzyme block). Anti-NK1.1-FITC (FITC, fluorescein isothiocyanate) and anti-granzyme B-FITC were used at 1 mg/mL and 2.5 mg/mL, respectively. Anti-FITC (Pierce) was used as recommended by the manufacturers. Horseradish peroxidase was developed with DAB (Dako) for 10 minutes. Slides were counterstained with hematoxylin, dehydrated in alcohol, and mounted in mounting medium (Sakura Finetek). Details are found in Supplementary Materials and Methods. Table SI ). By contrast, most M-control tumors continued to grow at the same rate. Regression of large IL-15-secreting tumors did not stop the growth of contralateral Mcontrol tumors suggesting that the effect of IL-15 is largely restricted to the local microenvironment of the IL-15-secreting tumor (Fig. 1D, middle) .
Densely granulated cells found in the regressing tumor
M-control tumors growing in anti-IL-15-treated Rag1 À/À mice were densely packed with viable cancer cells, many in mitosis; only the centers of these M-control tumors were necrotic ( Fig. 2A) . Cross-sections of regressing M-IL-15 tumors 12 days after final injection of anti-IL-15 showed mostly necrotic tumor tissue (Fig. 2B ). The few partially viable areas were packed with densely granulated cells and it was difficult to identify any remaining viable cancer cells. The granules stained bright magenta with periodic acidSchiff (PAS) and were resistant to pretreatment with diastase. Some of these granulated cells in the regressing tumors were undergoing mitosis suggesting that the granulated cells represented infiltrating host cells rather than thanatosomes derived of dying cancer cells ( Table SI) . Flow cytometry revealed that the tumor-infiltrating NK cells expressed normal levels of NKp46, 2B4, and CD122 but reduced levels of DX5 and NKG2D, compared with splenic NK cells (Fig. 4D) ; differences in marker expression were not due to differences in sample preparation (data not shown). The infiltrating NK cells also had decreased CD27, an immature NK cell marker, and increased 4-1BB, CD11b, and TRAIL expression, characteristic of activated NK cells (33, 34) . Despite the similarities to activated NK cells, we found no PAS þ NK cells in spleens from poly I:C activated wild-type mice (data not shown), nor in short-term cultures of NK cells activated with IL-15 ( Supplementary Fig S2A) . Also, mice with heavily infiltrated M-IL-15 tumors had only very few granulated NK cells in their spleens ( Supplementary  Fig S2B) . Microscopic analysis from serial sacrifices showed that the NK cells took time to mature into granular PAS þ cells and could not be detected in tumors as early as 3 days post cancer cell injection but were present by day 12 ( Supplementary Fig. S3 ).
An analysis of cytokines that may have synergized with IL-15 to promote the differentiation of densely granular NK cells was conducted. CD11b þ stromal cells in growing M-IL-15 tumors expressed IL-12 and IL-10, but no detectable IL18 and TGF-b ( Supplementary Fig. S4 ). Cancer cells obtained from growing tumors or cultured in vitro did not express any of these cytokines at detectable levels ( Supplementary Fig. S4 and data not shown, respectively).
Eradication depends on perforin released by infiltrating NK cells and destruction of cancer cells at the tumor margin
Given the prominent granules found in M-IL-15 tumors, we hypothesized that perforin was involved in tumor rejection. We evaluated the rejection of M-IL-15 tumors grown in Rag1 À/À Prf1 À/À mice with anti-IL-15 antibody after antibody treatment was stopped. Indeed, in the absence of perforin, we found M-IL-15 tumors grew with similar kinetics to viable M-control tumors (compare left with right of Fig. 1D ; Supplementary Table SI) . Surprisingly, the tumors growing in Rag1 À/À Prf1 À/À mice were mostly necrotic ( showed that NK cells can be found in the peripheral blood early but not later, when tumors began to relapse (Fig. 6C) . Taken together, IL-15Ra expression seems to be required on stromal cells to achieve complete tumor eradication. A mixture containing 5% of non-IL-15-secreting cancer cells never formed tumors (Supplementary Fig. S5A ). ( Supplementary Fig S5B) , all IL-15-secreting cells were specifically deleted.
Several cancer cell lines induce densely granulated NK cells
We transduced 3 other cancer cell lines to express IL-15 and/or IL-15Ra at high levels ( Supplementary Fig. S6 ). Both cancer lines expressing IL-15 and Ra, C3H/HeN-derived AG104A-IL-15-Ra, and C57BL/6-derived 9604-IL-15-Ra formed viable tumors when injected in syngeneic mice pretreated with anti-IL-15 antibody. Histology of tumors from nontreated animals showed destruction of cancer cells and infiltration by densely granulated NK cells ( Fig.  7A and B) .
The IL-15Ra-deficient cancer line 8215 was transduced to express IL-15 only (Supplementary Fig. S6 ). This line also formed viable tumors in Rag1 À/À Prf1 À/À mice (Fig. 7C) . In 
Discussion
We show that IL-15-induced NK cells can eliminate large established solid tumors in a host completely devoid of T and B cells. This unprecedented effect was apparently caused by massive influx of a unique type of very densely granulated NK cells that resemble a NK subtype described in the mammalian uterus during pregnancy (uNK; ref. 35 ) that also depends on IL-15 (36) . Unlike granulocytes, which are end stage cells, these heavily granulated NK cells were still clearly proliferating at the tumor site. Other mature NK cells can also undergo blastogenesis such as virally induced NK cells in the spleen (37) and uNK cells in the uterus (38) . As described for mature uNK cells, the granules of the IL-15-induced NK cells in the tumor tissue were PAS-positive and diastase resistant and their cytoplasmic membrane stained with the lectin DBA, which binds to glycoconjugates containing N-acetyl-D-galactosamine. However, it may be inappropriate to draw further analogies between the densely granulated NK cells described here and uNK because the tumor-infiltrating IL-15-induced NK cells are a cytolytic population generated by manipulating the tumor microenvironment. Also, although perforin is required for the eradication of tumors by these granulated NK cells, uNK do not need perforin for successful pregnancies (39) . Transgenic mice overexpressing secreted IL-15 do not show densely granulated NK cells in their spleen, liver, or gut (data not shown), nor do short-term cultures of wild-type or IL-15-transgenic splenic NK cells stimulated with high-dose IL-15. The difference to IL-15-secreting tumors might be the level of IL-15 secretion and/or IL-15Ra expression, but also the presence of other cytokines. IL-12 was shown to increase the production of NK effector cytokines and IFN-g while it suppressed target killing (40, 41) . IL-10, in contrast, was recently shown to enhance cytolytic activity of NK cells (42) . High local levels of IL-15 were, nevertheless, critical for the generation of densely granulated NK cells; cancer lines not expressing IL-15 induced only very few granulated cells ( Supplementary Fig  S2C) . Several methodologic differences to other studies expressing IL-15 in cancer cells could explain why such strong antitumor effects have not been described earlier. For example, earlier studies used human IL-15, which was not fused to any signaling peptide needed for effective secretion; comparison of ELISA data suggests up to 7,000-fold higher secretion of IL-15 (22) . Furthermore, it is not clear whether the cancers expressed IL-15Ra. More recent studies employing highly secreted IL-15 do show NK-dependent inhibition of tumor outgrowth, similar to what we find; whether rejection of established tumors was studied in these models has not been described (17, 18, 24) . We were able to study rejection of established tumors by growing them under protection of anti-IL-15 antibody, as transpresented IL-15 is needed for (i) augmenting susceptibility to killing (18) and (ii) survival of circulating NK cells. Interestingly, NK cells survived in the center of tumors growing in anti-IL-15-treated mice, consistent with the notion that antibodies cannot effectively diffuse into solid tumors (43) . The rim of these tumors remained NK cell free and viable, even shortly after cessation of the antibody treatment. Tumors began to regress approximately 10 days after the last dose of antibody when circulating and infiltrating NK cells were detected. It remains unclear whether these NK cells originated from the surviving NK cells within the tumor or whether they infiltrated from the periphery and matured in the tumor. 
Rag1
-/-IL-15Rα -/-hosts Tumors in mice lacking perforin had vast central necrosis while the rim remained viable. It is tempting to speculate that the destruction of the greater mass of the tumor was caused by IFN-g and TNF still being produced by the perforin-deficient IL-15-induced NK cells, as IFN-g was shown to be an important effector molecule in adoptively transferred NK cells (44) . Furthermore, infiltrated NK cells had upregulated 4-1BB, which has been implicated with elevated IFN-g secretion (45 (48) . Once a proper delivery approach is developed, these effector NK cells need to be induced only in the microenvironment of the tumor margin sparing the rest of the body from the side effects and suffering that accompany many available therapies today.
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